Measles Virus as an Oncolytic Immunotherapy.
cancer immunotherapy
immune checkpoint blockade
measles virus
oncolytic virus
vaccination
vector engineering
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
01 Feb 2021
01 Feb 2021
Historique:
received:
31
12
2020
revised:
19
01
2021
accepted:
26
01
2021
entrez:
4
2
2021
pubmed:
5
2
2021
medline:
5
2
2021
Statut:
epublish
Résumé
Measles virus (MeV) preferentially replicates in malignant cells, leading to tumor lysis and priming of antitumor immunity. Live attenuated MeV vaccine strains are therefore under investigation as cancer therapeutics. The versatile MeV reverse genetics systems allows for engineering of advanced targeted, armed, and shielded oncolytic viral vectors. Therapeutic efficacy can further be enhanced by combination treatments. An emerging focus in this regard is combination immunotherapy, especially with immune checkpoint blockade. Despite challenges arising from antiviral immunity, availability of preclinical models, and GMP production, early clinical trials have demonstrated safety of oncolytic MeV and yielded promising efficacy data. Future clinical trials with engineered viruses, rational combination regimens, and comprehensive translational research programs will realize the potential of oncolytic immunotherapy.
Identifiants
pubmed: 33535479
pii: cancers13030544
doi: 10.3390/cancers13030544
pmc: PMC7867054
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : EN_1119_2-2
Organisme : Wilhelm Sander-Stiftung
ID : 2018.058.1
Références
Mol Ther. 2012 Jun;20(6):1139-47
pubmed: 22334023
Cancer Gene Ther. 2006 Aug;13(8):732-8
pubmed: 16543921
Int J Oncol. 2013 Jul;43(1):103-12
pubmed: 23612727
J Gen Virol. 2011 Jun;92(Pt 6):1458-1466
pubmed: 21325484
Gene Ther. 2007 Feb;14(4):324-33
pubmed: 17051248
Methods Mol Biol. 2011;737:345-66
pubmed: 21590404
BMC Cancer. 2019 Dec 3;19(1):1172
pubmed: 31795974
J Exp Clin Cancer Res. 2019 Sep 18;38(1):408
pubmed: 31533779
Gene Ther. 2011 Mar;18(3):313-7
pubmed: 21068781
Mol Ther. 2011 Jun;19(6):1034-40
pubmed: 21427708
Oncotarget. 2017 Jun 27;8(38):63096-63109
pubmed: 28968974
Blood. 2014 Feb 27;123(9):1327-35
pubmed: 24345754
Proc Natl Acad Sci U S A. 2019 Jun 11;116(24):11587-11589
pubmed: 31138700
J Biol Chem. 2008 Apr 25;283(17):11763-71
pubmed: 18292085
Hum Gene Ther. 2008 Jul;19(7):690-8
pubmed: 18576918
Cytokine Growth Factor Rev. 2020 Dec;56:28-38
pubmed: 32660751
Hum Vaccin Immunother. 2016 May 3;12(5):1102-16
pubmed: 26631840
Oncotarget. 2015 Dec 29;6(42):44892-904
pubmed: 26539644
Virus Res. 2019 Apr 2;263:145-150
pubmed: 30684519
Mol Ther. 2011 Oct;19(10):1813-20
pubmed: 21610701
Cancer Res. 2008 Jun 15;68(12):4882-92
pubmed: 18559536
EMBO J. 1995 Dec 1;14(23):5773-84
pubmed: 8846771
Viruses. 2016 Sep 20;8(9):
pubmed: 27657109
Viruses. 2016 Oct 22;8(10):
pubmed: 27782084
Cancer Sci. 2014 Feb;105(2):211-8
pubmed: 24238277
Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):E554-62
pubmed: 24449891
Blood Adv. 2018 Dec 11;2(23):3492-3505
pubmed: 30530776
Gene Ther. 2013 Jan;20(1):7-15
pubmed: 22170342
J Virol. 2007 Mar;81(6):2564-72
pubmed: 17182683
Mol Ther. 2011 Jun;19(6):1097-106
pubmed: 21468006
Nat Med. 2002 May;8(5):527-31
pubmed: 11984600
Cancer Res. 2003 Oct 1;63(19):6463-8
pubmed: 14559838
Int J Oncol. 2009 May;34(5):1247-56
pubmed: 19360338
PLoS Comput Biol. 2019 Mar 5;15(3):e1006773
pubmed: 30835721
Gene Ther. 2013 Nov;20(11):1033-41
pubmed: 23719065
Sci Rep. 2017 Jul 12;7(1):5170
pubmed: 28701757
Clin Cancer Res. 2013 Mar 1;19(5):1147-58
pubmed: 23339127
Mol Ther Oncolytics. 2016 Nov 02;3:16022
pubmed: 27847861
Cancer Res. 2004 Jul 15;64(14):4919-26
pubmed: 15256464
Cancer Res. 2009 Feb 15;69(4):1459-68
pubmed: 19208845
Viruses. 2020 Feb 21;12(2):
pubmed: 32098134
Neuro Oncol. 2017 Apr 1;19(4):493-502
pubmed: 27663389
Biomed Res Int. 2013;2013:387362
pubmed: 23586034
J Gen Virol. 2020 Apr;101(4):399-409
pubmed: 32053093
Bull Math Biol. 2010 Feb;72(2):469-89
pubmed: 19787406
Viruses. 2019 Aug 07;11(8):
pubmed: 31394824
Oncotarget. 2015 Jun 30;6(18):16019-30
pubmed: 25909216
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6170-8
pubmed: 17062694
Clin Pharmacol Ther. 2007 Dec;82(6):700-10
pubmed: 17971816
Blood. 2004 Mar 1;103(5):1641-6
pubmed: 14604966
Mol Oncol. 2016 Nov;10(9):1387-1403
pubmed: 27507538
Gynecol Oncol. 2013 Aug;130(2):362-8
pubmed: 23676551
Oncol Lett. 2019 Nov;18(5):5534-5542
pubmed: 31612061
Mol Cancer Res. 2017 Oct;15(10):1410-1420
pubmed: 28679779
Lancet. 1971 Jul 10;2(7715):105-6
pubmed: 4103972
Cancer Invest. 2018 Feb 7;36(2):106-117
pubmed: 29485292
J Virol. 1998 Apr;72(4):2905-16
pubmed: 9525611
Mol Ther Oncolytics. 2015 Oct 07;2:15019
pubmed: 27119111
Curr Opin Virol. 2020 Apr;41:85-97
pubmed: 32861945
Exp Hematol. 2013 Jun;41(6):508-17
pubmed: 23403007
Cancer Res. 2010 Feb 1;70(3):875-82
pubmed: 20103634
Clin Cancer Res. 2009 Dec 1;15(23):7246-55
pubmed: 19934299
Cancer Lett. 2019 Sep 28;460:108-118
pubmed: 31226409
Sci Rep. 2016 Apr 19;6:24572
pubmed: 27090874
Mol Ther. 2007 Nov;15(11):1991-7
pubmed: 17712331
Hum Gene Ther Clin Dev. 2016 Dec;27(4):145-151
pubmed: 27604429
Cancer Sci. 2016 Nov;107(11):1647-1652
pubmed: 27561180
Viruses. 2020 Feb 04;12(2):
pubmed: 32033013
Hum Gene Ther. 2013 May;24(5):554-64
pubmed: 23550539
Leukemia. 2020 Dec;34(12):3310-3322
pubmed: 32327728
Blood. 2003 Apr 1;101(7):2557-62
pubmed: 12433686
Clin Cancer Res. 2018 May 1;24(9):2128-2137
pubmed: 29437789
J Virol. 2013 Mar;87(6):3484-501
pubmed: 23302892
Gene Ther. 2013 Apr;20(4):444-9
pubmed: 22914495
Virus Genes. 2017 Oct;53(5):733-740
pubmed: 28710608
Mol Ther. 2008 Sep;16(9):1556-64
pubmed: 18665158
Mol Ther Oncolytics. 2018 Dec 15;12:68-78
pubmed: 30705967
Cell. 1998 Aug 21;94(4):471-80
pubmed: 9727490
Crit Rev Biotechnol. 2020 Mar;40(2):247-264
pubmed: 31918573
Mol Ther. 2010 Mar;18(3):544-51
pubmed: 20051938
Mol Ther. 2007 Apr;15(4):651-9
pubmed: 17299401
Gene Ther. 2008 Jul;15(14):1024-34
pubmed: 18356818
J Virol. 1996 Jul;70(7):4200-4
pubmed: 8676439
Int J Oncol. 2016 Nov;49(5):1931-1944
pubmed: 27601235
Hum Gene Ther Clin Dev. 2013 Mar;24(1):11-22
pubmed: 23692379
Mol Ther. 2009 Jun;17(6):1012-21
pubmed: 19277014
Cancer Gene Ther. 2010 Aug;17(8):550-8
pubmed: 20379224
J Gen Virol. 2006 Jun;87(Pt 6):1643-1648
pubmed: 16690929
Blood. 2001 Jun 15;97(12):3746-54
pubmed: 11389012
Mol Ther Oncolytics. 2017 Sep 29;7:57-66
pubmed: 29367943
Cancer Res. 2013 Jan 15;73(2):865-74
pubmed: 23293278
Mol Ther. 2007 Mar;15(3):588-97
pubmed: 17245355
Clin Cancer Res. 2007 Dec 1;13(23):7155-65
pubmed: 18056196
Cancer Gene Ther. 2011 Aug;18(8):598-608
pubmed: 21701532
Front Oncol. 2019 Jan 15;8:676
pubmed: 30697531
J Natl Cancer Inst. 2018 Oct 1;110(10):1123-1132
pubmed: 29788332
Methods Mol Biol. 2020;2058:111-126
pubmed: 31486034
Mol Ther. 2007 Jan;15(1):114-22
pubmed: 17164782
Cancer Res. 2006 Dec 15;66(24):11840-50
pubmed: 17178881
Exp Hematol. 2006 Jun;34(6):713-20
pubmed: 16728275
Math Biosci. 2006 Jan;199(1):55-78
pubmed: 16376950
Eur J Immunol. 2016 Apr;46(4):919-28
pubmed: 26763072
Mol Ther. 2016 Feb;24(1):184-92
pubmed: 26278331
Cancer Res. 2015 Jan 1;75(1):22-30
pubmed: 25398436
Sci Rep. 2017 Dec 4;7(1):16892
pubmed: 29203786
Int J Cancer. 2014 Jan 1;134(1):235-43
pubmed: 23797800
Blood. 2005 Oct 1;106(7):2287-94
pubmed: 15961518
Oncotarget. 2015 Jan 30;6(3):1544-55
pubmed: 25575816
Oncolytic Virother. 2018 Apr 30;7:37-41
pubmed: 29750140
J Theor Biol. 2008 May 7;252(1):109-22
pubmed: 18316099
Curr Gene Ther. 2017;16(6):419-428
pubmed: 28042780
Gene Ther. 2012 Mar;19(3):279-87
pubmed: 21753796
Sci Rep. 2019 May 1;9(1):6767
pubmed: 31043633
Hum Gene Ther. 2013 Jul;24(7):644-54
pubmed: 23642239
Mol Ther. 2013 Apr;21(4):849-59
pubmed: 23380817
Oncoimmunology. 2016 Nov 18;6(1):e1261240
pubmed: 28197384
Mol Ther. 2003 Jan;7(1):62-72
pubmed: 12573619
Cell. 2018 Aug 9;174(4):1031-1032
pubmed: 30096300
Gene Ther. 2013 Mar;20(3):255-61
pubmed: 22476202
Viruses. 2019 Oct 03;11(10):
pubmed: 31623390
J Immunol. 2012 Feb 1;188(3):1002-10
pubmed: 22180616
Cancer Gene Ther. 2012 Mar;19(3):202-11
pubmed: 22116376
Cancer Res. 2010 Oct 1;70(19):7620-9
pubmed: 20858718
Cochrane Database Syst Rev. 2020 Apr 20;4:CD004407
pubmed: 32309885
Virology. 2015 May;479-480:331-44
pubmed: 25702088
Cancer Res. 2003 May 15;63(10):2462-9
pubmed: 12750267
Mol Ther. 2020 Apr 8;28(4):1043-1055
pubmed: 32087150
Mol Ther. 2014 Nov;22(11):1949-59
pubmed: 25156126
Trends Microbiol. 2012 Sep;20(9):429-39
pubmed: 22721863
Anticancer Res. 2019 Jul;39(7):3727-3737
pubmed: 31262899
Mol Ther Methods Clin Dev. 2016 Apr 06;3:16018
pubmed: 27088104
Cancer Res. 2006 Aug 1;66(15):7694-700
pubmed: 16885371
Mol Ther. 2010 Jun;18(6):1155-64
pubmed: 20234340
J Invest Dermatol. 2013 Apr;133(4):1034-42
pubmed: 23223133
J Virol. 2017 Apr 28;91(10):
pubmed: 28250131
Cancer Res. 2007 Nov 15;67(22):10939-47
pubmed: 18006839
Blood. 2001 Oct 1;98(7):2002-7
pubmed: 11567982
Breast Cancer Res Treat. 2010 Aug;122(3):745-54
pubmed: 19894113
Cytokine Growth Factor Rev. 2020 Dec;56:39-48
pubmed: 32718830
Cancer Gene Ther. 2019 Mar;26(3-4):59-73
pubmed: 30177818
Nature. 2011 Nov 02;480(7378):530-3
pubmed: 22048310
Leukemia. 2017 Dec;31(12):2791-2798
pubmed: 28439108
J Virol. 2014 May;88(9):5152-64
pubmed: 24574393
Oncoimmunology. 2017 Jan 31;6(4):e1285992
pubmed: 28507792
Mol Ther Oncolytics. 2018 Dec 31;12:147-161
pubmed: 30775418
Cancer Gene Ther. 2013 Nov;20(11):630-7
pubmed: 24157925
J Gene Med. 2012 Sep-Oct;14(9-10):590-7
pubmed: 23015290
Nat Rev Neurosci. 2005 Jan;6(1):11-22
pubmed: 15611723
Mayo Clin Proc. 2014 Jul;89(7):926-33
pubmed: 24835528
Nat Biotechnol. 2005 Feb;23(2):209-14
pubmed: 15685166
BMC Cancer. 2014 Mar 19;14:206
pubmed: 24646176
Proc Natl Acad Sci U S A. 2020 Dec 22;117(51):32657-32666
pubmed: 33257540
Cancer Res. 2002 Aug 15;62(16):4656-62
pubmed: 12183422
Lancet. 2017 Dec 2;390(10111):2490-2502
pubmed: 28673424
PLoS One. 2014 Nov 12;9(11):e112014
pubmed: 25390891